Your browser doesn't support javascript.
loading
Prevalence of sarcopenic obesity in patients with diabetes and adverse outcomes: A systematic review and meta-analysis.
Zhou, Yuan-Yuan; Wang, Jin-Feng; Yao, Qian; Jian, Qiu-Feng; Luo, Zhi-Peng.
Affiliation
  • Zhou YY; Chengdu University of Traditional Chinese Medicine, Sichuan, 610075, China.
  • Wang JF; Chengdu University of Traditional Chinese Medicine, Sichuan, 610075, China.
  • Yao Q; Chengdu Second People's Hospital, Sichuan, 610017, China. Electronic address: qianyaocdsdermyy@163.com.
  • Jian QF; Chengdu University of Traditional Chinese Medicine, Sichuan, 610075, China.
  • Luo ZP; The Tibet Autonomous Region People's Government Office in a Hospital in Chengdu, Chengdu, Sichuan, 610000, China.
Clin Nutr ESPEN ; 58: 128-135, 2023 12.
Article in En | MEDLINE | ID: mdl-38056996
ABSTRACT
BACKGROUND &

AIMS:

Sarcopenic obesity (SO), which refers to the coexistence of sarcopenia and obesity. The aim of this systematic review and meta-analysis was first to assess the prevalence of SO in patients with diabetes, and second, to evaluate possible adverse outcomes.

METHODS:

This study was conducted in adherence to the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines and the data were collated by means of meta-analysis and narrative synthesis. We comprehensively and systematically searched PubMed, Embase, Web of Science, CBM, CNKI, Wanfang Database from the establishment of the database to December 2022, and collected related studies on SO in patients with diabetes. Using Stata 16.0 software to pool the estimates for the prevalence of SO in patients with diabetes, and a descriptive systematic review of possible adverse outcomes was performed.

RESULTS:

The prevalence of 20 included studies were pooled by a random-effects model, which showed that the prevalence of SO in patients with diabetes was 27%. Subgroup analyses showed that the prevalence of SO was higher among studies using BIA (24%) to assess muscle mass, and those focused on literature of moderate-quality (29%), being published from 2013 to 2016 (29%), female patients with diabetes (17%), North Americans (30%). SO in patients with diabetes can lead to adverse outcomes including decreased glomerular filtration rate, massive proteinuria, cognitive decline, and insulin resistance.

CONCLUSION:

The systematic review and meta-analysis revealed a prevalence of 27% for SO in patients with diabetes, and it is associated with potential serious adverse outcomes. Therefore, we should attach importance to the screening of SO in patients with diabetes and early detection of susceptible groups, then selecting appropriate interventions to reduce the occurrence of it and various adverse outcomes in this demographic.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Insulin Resistance / Diabetes Mellitus / Sarcopenia Type of study: Systematic_reviews Limits: Female / Humans Language: En Journal: Clin Nutr ESPEN Year: 2023 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Insulin Resistance / Diabetes Mellitus / Sarcopenia Type of study: Systematic_reviews Limits: Female / Humans Language: En Journal: Clin Nutr ESPEN Year: 2023 Document type: Article